RTP Mobile Logo
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Colorectal Cancer (Webinar Video Proceedings)
Released February 2022

Featuring perspectives from Drs Kristen Ciombor, Cathy Eng, Pashtoon Kasi, Christopher Lieu and Alan Venook. Published February 8, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal cancer.


    • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering clinical and biologic factors such as age, performance status and disease stage.
    • Develop a long-term plan to guide the selection and sequencing of therapy for patients diagnosed with metastatic CRC (mCRC), considering biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals for treatment.
    • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into care.
    • Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future role of various investigational approaches.
    • Evaluate available data with and FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient mCRC, and optimally select patients for these approaches.
    • Apply available and emerging research to optimize the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC.
    • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to refer appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOGI22/CRC/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Kristen K Ciombor, MD, MSCI
    Associate Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee

    Advisory Committee: Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: Merck, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc.

    Cathy Eng, MD
    Professor of Medicine
    Co-Leader, VICC Gastrointestinal Cancer Research Program
    David H Johnson Chair in Surgical and Medical Oncology
    Co-Director, GI Oncology
    Director, VICC Young Adults Program
    Co-Chair, NCI Gastrointestinal Steering Committee
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Gilead Sciences Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Natera Inc; Contracted Research: Elevar Therapeutics, Hutchison MediPharma; Data and Safety Monitoring Board/Committee: Mirati Therapeutics, Veloxis Pharmaceuticals.

    Pashtoon M Kasi, MD, MS
    Director, Colon Cancer Research
    Director, Liquid Biopsy Research
    Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
    Englander Institute for Precision Medicine
    Division of Hematology and Medical Oncology
    NewYork-Presbyterian Hospital/Weill Cornell Medicine
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Axiom Healthcare Strategies, Bayer HealthCare Pharmaceuticals, Boston Healthcare Associates Inc, Delcath Systems Inc, Exact Sciences Inc, Foundation Medicine, Inflection Point Biomedical Advisors, Ipsen Biopharmaceuticals Inc (institution), Lilly, Merck Sharp & Dohme Corp, Natera Inc, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Taiho Pharmaceutical Group, Tempus; Contracted Research: Advanced Accelerator Applications, Array BioPharma Inc, a subsidiary of Pfizer Inc, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, TerSera Therapeutics LLC; Travel, Accommodations, Expenses: AstraZeneca Pharmaceuticals LP.

    Christopher Lieu, MD
    Associate Professor of Medicine
    Associate Director for Clinical Research
    Co-Director, GI Medical Oncology
    University of Colorado Cancer Center
    Aurora, Colorado

    No relevant conflicts of interest to disclose.

    Alan P Venook, MD
    The Madden Family Distinguished Professor of Medical Oncology and Translational Research
    Shorenstein Associate Director, Program Development
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California

    Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Exelixis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Pierre Fabre, QED Therapeutics, a BridgeBio company.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Natera Inc and Taiho Oncology Inc.

    Release date: February 2022
    Expiration date: February 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):